The estimated Net Worth of Bhaskar Anand is at least 4.71 百万$ dollars as of 5 September 2023. Mr Anand owns over 406 units of Reata Pharmaceuticals Inc stock worth over 4,151,980$ and over the last 3 years he sold RETA stock worth over 554,326$.
Mr has made over 6 trades of the Reata Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 406 units of RETA stock worth 68,695$ on 5 September 2023.
The largest trade he's ever made was selling 2,343 units of Reata Pharmaceuticals Inc stock on 14 June 2023 worth over 239,244$. On average, Mr trades about 475 units every 17 days since 2022. As of 5 September 2023 he still owns at least 24,089 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr Anand stock trades at the bottom of the page.
Bhaskar Anand is the VP & Chief Accounting Officer at Reata Pharmaceuticals Inc.
Mr Anand is 44, he's been the VP & Chief Accounting Officer of Reata Pharmaceuticals Inc since . There are 11 older and 4 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
Bhaskar's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131.
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over 176,850,875$ worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth 179,313,590$ . The most active insiders traders include Holdings A/S Novo、R Kent Jr Mc Gaughy、Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of 10,950,893$. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth 546,195$.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: